Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)

Exclusion Criteria

• •Patient was pregnant or a nursing mother
• •Patient had abused drugs or alcohol within 12 months prior to entering the study
• •Patient had a history of cardiovascular disease
• •Patient had clinically significant Electrocardiography (ECG) abnormality
• •Patient had a resting systolic blood pressure of greater than 145 mm Hg or diastolic of less than 95 mm Hg at screening
• •Patient received treatment with an investigational device or compound within 30 days of the study start
• •Patient typically suffered from less then 1 or more than 8 attacks of migraine per month
• •Patient had difficulty in distinguishing his/her migraine attacks from tension or interval headaches
• •Patient had hypersensitivity to sumatriptan
• •Patient had participated in any previous study involving rizatriptan